Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Tumor Boards
Colleague Insights
Living Resources
Conferences
Nursing Perspectives
Video Expert Opinion
Sign in
Join now
Jean-Yves Douillard MD, PhD
Jean-Yves Douillard MD, PhD Advisory Board
Roger Stupp MD
Roger Stupp MD Advisory Board
Eric Jonasch MD
Eric Jonasch MD Advisory Board
See All Experts
featured
Published in Oncology and
1 other channel

Expert Opinion / Commentary · April 09, 2015

VIDEO: Alternate Dose Scheduling Strategies in RCC

Eric Jonasch MD

 

 Save  Recommend
 Share

Additional Info

  1. Atkinson BJ, Kalra S, Wang X, et al. Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules. J Urol. 2014;191(3):611-618.
  2. Lee JL, Kim MK, Park I, et al. Randomized phase II trial of sunitinib four-week on and two-week off versus two-week on and one-week off in metastatic clear cell type renal cell carcinoma: RESTORE trial. J Clin Oncol 33, 2015 (suppl 7; abstr 427)
  3. Najjar YG, Mittal K, Elson P, et al. A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma. Eur J Cancer. 2014;50(6):1084-1089.
  4. Bjarnason GA, Khalil B, Hudson JM, et al. Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: correlation with dynamic microbubble ultrasound data and review of the literature. Urol Oncol. 2014;32(4):480-487.

Disclosure statements are available on the authors' profiles:

Eric Jonasch MD

Further Reading

Most Watched This Week

Related Videos